UNSPSC 51291800: Antidepressant amides

Antidepressant drugs made from organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group.

UNSPSC 51291800 Antidepressant amides is a Class code that in practice captures a much broader range of pharmaceutical procurement than its nominal scope suggests. State and local governments soliciting under this code are buying generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and related pharmacy benefit program services. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering procurement on behalf of participating jurisdictions and public facilities. Vendors are expected to hold current Good Manufacturing Practice (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance certifications, maintain relationships with authorized pharmaceutical wholesalers, and provide detailed product information including National Drug Codes, SKUs, and pricing in multiple formats (flat price, net price, WAC-minus). Contracts typically require comprehensive insurance coverage, E-Verify compliance, and adherence to federal regulations such as the Clean Air Act when procurement is federally funded.

Recent activity spans Florida, Texas, and Minnesota with multistate reach. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 with a July 26, 2023 response deadline for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission posted a Request for Information (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with awards effective July 1, 2026. The MMCAP RFP evaluated proposals on price competitiveness (75 percent), fixed pricing (10 percent), and compliance factors, and reserved the right to make sole, dual, or multi-awards.